https://canerozy.com/en/articles/ Evidence-based scientific essays and clinical reviews on metabolism, obesity etiology, and nutrition. en-US Mon, 26 Oct 2026 15:35:41 -0000 https://canerozy.com/en/articles/is-sleep-a-dietary-risk-factor.html https://canerozy.com/en/articles/is-sleep-a-dietary-risk-factor.html Thu, 22 Oct 2026 00:00:00 -0000 Can inadequate sleep be classified as a dietary risk factor? Analyzing clinical trials on ghrelin, leptin, ultra-processed cravings, and fat loss. https://canerozy.com/en/articles/fasting-with-insulin-resistance.html https://canerozy.com/en/articles/fasting-with-insulin-resistance.html Tue, 20 Oct 2026 00:00:00 -0000 Why fasting with insulin resistance may not yield expected fat loss. Exploring chronic hyperinsulinemia, muscle catabolism, and circadian feeding. https://canerozy.com/en/articles/intermittent-fasting-gut-microbiome.html https://canerozy.com/en/articles/intermittent-fasting-gut-microbiome.html Thu, 08 Oct 2026 00:00:00 -0000 Strict intermittent fasting not yielding results? Emerging research shows gut microbiome composition and Akkermansia levels dictate metabolic response. https://canerozy.com/en/articles/diet-epigenetically-programming-liver-cancer.html https://canerozy.com/en/articles/diet-epigenetically-programming-liver-cancer.html Tue, 06 Oct 2026 00:00:00 -0000 Years of high-fat nutrition can epigenetically reprogram liver cells long before tumors appear. Discover how diet alters chromatin and cancer risk. https://canerozy.com/en/articles/can-nutrients-naturally-stimulate-glp-1.html https://canerozy.com/en/articles/can-nutrients-naturally-stimulate-glp-1.html Thu, 01 Oct 2026 00:00:00 -0000 Can nutrients naturally stimulate GLP-1? We explore the physiology of dietary fiber, protein, and gut L-cells in triggering natural incretin secretion. https://canerozy.com/en/articles/patients-resistant-to-glp-1-therapies.html https://canerozy.com/en/articles/patients-resistant-to-glp-1-therapies.html Tue, 29 Sep 2026 00:00:00 -0000 Why do some patients fail to lose weight on GLP-1 therapies? We examine non-responder phenotypes, genetic polymorphisms, and resistance mechanisms. https://canerozy.com/en/articles/glucagon-paradox-blood-sugar-raising-hormone-weight-loss.html https://canerozy.com/en/articles/glucagon-paradox-blood-sugar-raising-hormone-weight-loss.html Thu, 24 Sep 2026 00:00:00 -0000 How does glucagon, a blood sugar-raising hormone, induce weight loss? Unpacking the glucagon paradox and next-generation tri-agonists like retatrutide. https://canerozy.com/en/articles/glp-1-exit-strategy-discontinuing-therapy.html https://canerozy.com/en/articles/glp-1-exit-strategy-discontinuing-therapy.html Tue, 22 Sep 2026 00:00:00 -0000 What happens when you discontinue GLP-1 incretin therapy? Evidence on metabolic adaptation, weight regain, and clinical maintenance exit strategies. https://canerozy.com/en/articles/muscle-mass-panic-with-glp-1.html https://canerozy.com/en/articles/muscle-mass-panic-with-glp-1.html Thu, 17 Sep 2026 00:00:00 -0000 Is muscle loss on GLP-1 agonists cause for panic? Reviewing DEXA body composition data, lean mass ratios, and dietary protein intake strategies. https://canerozy.com/en/articles/glp-1-agonists-weight-loss-vs-obesity-treatment.html https://canerozy.com/en/articles/glp-1-agonists-weight-loss-vs-obesity-treatment.html Tue, 15 Sep 2026 00:00:00 -0000 Do GLP-1 receptor agonists truly treat obesity as a chronic disease or just reduce body mass? A critical review of EASO guidelines and adipose health. https://canerozy.com/en/articles/feeling-full-on-glp-1-cells-starving.html https://canerozy.com/en/articles/feeling-full-on-glp-1-cells-starving.html Wed, 09 Sep 2026 00:00:00 -0000 Suppressed appetite on GLP-1 does not mean your cells are nourished. Learn why hidden malnutrition and micronutrient deficiencies emerge during therapy.